IART, US4579852082

Wells Fargo cuts target for Integra LifeSciences stock from USD 18 to USD 15

Published on 10/05/2026 at 14:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Integra cut 2026 revenue outlook to USD 1.634-1.654 billion. Integra LifeSciences stock costs EUR 11.40 on October 5, 2026 after EUR 11.35.

IART, US4579852082, Illustration mit AI erstellt.

Wells Fargo cut its price target for Integra LifeSciences stock from USD 18.00 to USD 15.00 while maintaining an Equal Weight rating, according to Investing.com on October 5, 2026. Integra stock was trading at EUR 11.40 at Lang & Schwarz on October 5, 2026 at 2:08 p.m. CEST, up 0.44 percent versus the prior close of EUR 11.35 on October 2, 2026.

Guidance falls after flooding

Integra cut its full-year 2026 reported revenue outlook from USD 1.654 billion to USD 1.695 billion to USD 1.634 billion to USD 1.654 billion. The company also reduced adjusted earnings per diluted share guidance from USD 2.40 to USD 2.50 to USD 2.30 to USD 2.40, according to its October 2, 2026 release.

The same release projected third-quarter 2026 revenue of USD 410 million to USD 412 million and adjusted earnings per diluted share of USD 0.55 to USD 0.59. Integra said flooding at its Cincinnati facility affected production, with full manufacturing operations expected to return during the second quarter of 2027.

Cash flow supports refinancing

Integra expects third-quarter 2026 operating cash flow above USD 85 million and full-year 2026 operating cash flow of USD 190 million to USD 200 million, according to Integra LifeSciences.

The company also launched a proposed USD 600 million seven-year senior secured Term Loan B to refinance existing debt and related fees. GlobeNewswire reported the announcement on October 2, 2026, while noting that completion remains subject to market and customary conditions.

Stock stays below yearly high

On Nasdaq, Integra was last at USD 12.68 on October 2, 2026 at 4:00 p.m. ET. Its 52-week range was USD 8.70 to USD 20.49, and its market capitalization was USD 986.2 million on that quote date.

For investors, the central tension is clear: the latest guidance lowers near-term earnings expectations, while projected operating cash flow and the refinancing plan support liquidity. The next major valuation test is whether Cincinnati production returns during the second quarter of 2027 as planned.